Glaxo pays $155M for Lunesta rights

GlaxoSmithKline will fork over up to $155 million to commercialize the sleep aid Lunesta outside of North America and Japan. Made by Sepracor, the drug will be sold under the brand name Lunivia; it's under regulatory review in Europe, and could get the go-ahead in up to 27 E.U. nations.

Lunesta has been a cash cow for Sepracor, delivering some $567 million in 2006 sales. The market for insomnia drugs in Europe is worth about $500 million--and that's with only 24 percent of insomniacs being treated. In other words, there's lots of upside on the continent.

- see the GlaxoSmithKline reelease
- read the Boston Business Journal report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

North Korean hackers were accused of posing as corporate recruiters in a scheme to breach AstraZeneca's computer systems and steal COVID-19 research.

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

McKinsey & Company helped guide Purdue's strategy for years and pitched the idea of rebates to distributors for overdoses, according to the NYT.